Brevan Howard Capital Management’s Moderna MRNA Stock Holding History

Brevan Howard Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.7M	Buy	181,105 +91,511	+102%	+$4.73M	0.09%	143
2026 Q1	$4.55M	Buy	89,594 +78,865	+735%	+$3.68M	0.04%	262
2025 Q4	$316K	Buy	+10,729	New	+$291K	﹤0.01%	1344
2024 Q3	–	Sell	-3,146	Closed	-$374K	–	1326
2024 Q2	$374K	Buy	+3,146	New	+$398K	﹤0.01%	704
2023 Q4	–	Sell	-157,000	Closed	-$16.2M	–	1071
2023 Q3	$16.2M	Hold	157,000	–	–	0.21%	23
2023 Q2	$19.1M	Sell	157,000 -103,000	-40%	-$13.7M	0.4%	18
2023 Q1	$39.9M	Buy	260,000 +30,000	+13%	+$4.95M	1.05%	17
2022 Q4	$41.3M	Sell	230,000 -270,000	-54%	-$44.1M	1.38%	11
2022 Q3	$59.1M	Buy	500,000 +220,000	+79%	+$33.4M	2.15%	10
2022 Q2	$40M	Buy	280,000 +225,000	+409%	+$32.2M	1.65%	12
2022 Q1	$9.47M	Buy	+55,000	New	+$9.26M	0.51%	13

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Brevan Howard Capital Management's MRNA Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Moderna (MRNA) stake by 102% in Q2 2026, buying an estimated $4.73M and bringing the position to 181,105 shares worth $12.7M. The position accounts for 0.09% of the portfolio, ranked #143.

Brevan Howard Capital Management first reported a position in MRNA in Q1 2022 and has held it in 11 quarters since. The position peaked at $59.1M in Q3 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Brevan Howard Capital Management held 181,105 shares of Moderna worth $12.7M as of Q2 2026.
Brevan Howard Capital Management bought 91,511 Moderna shares in Q2 2026, an estimated $4.73M.
Moderna made up 0.09% of Brevan Howard Capital Management's portfolio in Q2 2026, its #143 holding.
Brevan Howard Capital Management first reported a position in Moderna in Q1 2022 and has held it in 11 quarters since.
Brevan Howard Capital Management's Moderna position peaked at $59.1M in Q3 2022.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.